Skip to content

Assessment of Atrial Fibrillation in Emergency Department

Appréciation de la Prise en Charge de la Fibrillation Atriale Aux Urgences

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03836339
Acronym
ACFA
Enrollment
1369
Registered
2019-02-11
Start date
2018-10-01
Completion date
2019-12-31
Last updated
2021-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

emergency department, pathway of care, assessment, anticoagulants

Brief summary

Atrial Fibrillation (AF) is the most common disorder of the rhythm disturbance, especially in older adults. The incidence and prevalence of AF increases significantly with age: less than one new case per 1000/year before age 40 to 20/1000 per year after the age of eighty. AF represents 1% of emergency department (ED) visits a third of which are inaugural or recurrent. The causes are varied from cardiac (ischemic cardiac disease, valvular, high blood pressure, heart failure, pericarditis, myocarditis) to extra cardiac etiologies (pulmonary embolism, thyroid disorders, thyrotoxicosis, alcohol, shock, chest trauma, electrolyte disorders, dehydration). While the diagnosis is given quickly by reading the electrocardiogram (ECG), its management both in terms of therapeutic strategy that of choice of care pathway is complex as evidenced by the diversity of possibilities and the difference in practice. Specific recommendations have been published by the French Society of Emergency Medicine in 2015. Our study aims to investigate guidelines implementation in French ED, especially the contribution of diagnostic tests and initiated treatments. Therapeutic strategies are evaluated with a follow up at 3 months, 6 months and 1 year, reporting cardiovascular events and long-term treatment.

Detailed description

This study is non-interventional, recruiting patients presenting to ED with AF. No other epidemiological studies on the subject are available to calculate the required number of subjects and analyze the power of the study. Investigators planned to include 1 575 patients (45 patients in 35 centres) with a minimum targeted 1000 patients to be included in the 30-40 participating centers. The study aims to assess patients characteristics (age, sex, body mass index, type of AF, Congestive Heart failure Hypertension Age Diabetes Stroke - VAscular disease (CHA2DS2- VAsc) Score, Hypertension Abnormal liver/renal function, Stroke history, Bleeding history or predisposition, Labile INR, Elderly, Drug/alcohol usage (HAS-BLED) score), methods of diagnostic (blood tests, ECG, Imaging tests, Cardiac echography), treatment pattern (drugs administered in ED, drug prescribed at hospitalization discharge), patient pathway (orientation after ED admission, discharge, consultation planned), drug-related observance reported by the patient. Data are collected in a case report form (CRF). Source data verification is performed by sites investigators. A data dictionary containing detailed descriptions of each variable is shared with investigators. Sites monitoring is planned by a clinical research assistant for completing missing data. Statistical analysis: Data are medians and interquartile ranges (IQRs) for continuous variables, and numbers and percentages for qualitative variables. Stratified analysis of subgroups (age, sex, anticoagulant treatment, examination performed …) will be considered.

Interventions

None listed

Sponsors

French Cardiology Society
CollaboratorOTHER
French Society of Emergency Medicine
CollaboratorOTHER
Bayer
CollaboratorINDUSTRY
Boehringer Ingelheim
CollaboratorINDUSTRY
RESCUe - RESeau Cardiologie Urgence / RESUVal - RESeau des Urgences de la vallée du Rhône
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Atrial fibrillation diagnosis on ECG

Exclusion criteria

* Refusal of the patient to participate

Design outcomes

Primary

MeasureTime frameDescription
anticoagulant strategyat admissionanticoagulant therapy (vitamin K antagonist or direct oral anticoagulant) administration
Troponin valueAt admissionincidence of positive troponin
Brain Natriuretic Peptide (BNP/proBNP) valueAt admissionincidence of BNP elevation
Renal ClearanceAt admissionRenal clerance(Cl) measuring (by Cockroft formula : Cl(Male) = 1,23 x Weight (kg) x (140 - Age)/Creatinine, Cl(Female) = 1,04 x Weight (kg) x (140 - Age)/Creatinine)
cardiac echographyAt admissionnumber of cardiac echography performed in ED
antiarythmic drugsat admissionlist antiarythmic drugs administration (Class IA, IB, IC, II, III or IV of Vaughan Williams classification, digitalis or adenosin)
atrial fibrillation typeAt admissionNumber of idiopathic AF, AF secondary to acute heart failure, pulmonary embolism, COPD decompensation, pneumopathy, dysthyroidism, or any other precipitating factor.

Secondary

MeasureTime frameDescription
atrial fibrillation incidenceat 3 monthsnumber of patients with recurrent and persistent
stroke incidenceat admissionnumber of new strokes occured
myocardial infarction incidenceat admissionnumber of new myocardial infarctions occured
hemorrhagic eventsat admissiontype 1, 2 or 3 of the International Society on Thrombosis and Hemostasis classification
mortalityat 24 hours after admissionnumber of dead patients

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026